Literature DB >> 31571010

Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence.

Yuyang Ze1, Xiaowen Zhang2, Fei Shao2, Lin Zhu2, Shanmei Shen3, Dalong Zhu4, Yan Bi5.   

Abstract

PURPOSE: Papillary thyroid carcinoma (PTC), the most common malignant tumor of the thyroid, has been criticized as overtreated by some researchers in recent years. Active surveillance (AS) was first proposed at Kuma Hospital in 1993, and popularized in other institutes ever since. We provide a brief review of low-risk PTC active monitoring studies to date, and discuss the advantages of AS and limitations of existing studies.
RESULTS: Most papillary thyroid microcarcinomas do not show significant growth or new lymph node metastasis in a 10-year AS period. Patients who undergo delayed surgery during AS generally have a good prognosis. Tumor progression correlates with age, calcification pattern, and Ki-67 positivity. Serum thyroid stimulating hormone concentration and pregnancy might also influence tumor progression in some studies.
CONCLUSION: Active surveillance for low-risk PTC has shown its safety and feasibility in certain populations. In the future, it is warranted to determine valuable tumor progression predictors and most suitable PTC patients for AS.

Entities:  

Keywords:  Active surveillance; Low-risk; Observation; Papillary carcinoma; Thyroid

Mesh:

Year:  2019        PMID: 31571010     DOI: 10.1007/s00432-019-03021-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  49 in total

1.  Transoral endoscopic thyroidectomy vestibular approach (TOETVA): indications, techniques and results.

Authors:  Angkoon Anuwong; Thanyawat Sasanakietkul; Pornpeera Jitpratoom; Khwannara Ketwong; Hoon Yub Kim; Gianlorenzo Dionigi; Jeremy D Richmon
Journal:  Surg Endosc       Date:  2017-07-17       Impact factor: 4.584

2.  Excellence in robotic thyroid surgery: a comparative study of robot-assisted versus conventional endoscopic thyroidectomy in papillary thyroid microcarcinoma patients.

Authors:  Sohee Lee; Haeng Rang Ryu; Jae Hyun Park; Kyu Hyung Kim; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park
Journal:  Ann Surg       Date:  2011-06       Impact factor: 12.969

3.  Histological typing of thyroid tumours.

Authors:  L H Sobin
Journal:  Histopathology       Date:  1990-05       Impact factor: 5.087

4.  Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance.

Authors:  Akira Miyauchi; Takumi Kudo; Yasuhiro Ito; Hitomi Oda; Hisanori Sasai; Takuya Higashiyama; Mitsuhiro Fukushima; Hiroo Masuoka; Minoru Kihara; Akihiro Miya
Journal:  Surgery       Date:  2017-11-02       Impact factor: 3.982

5.  Papillary thyroid microcarcinoma might progress during pregnancy.

Authors:  Hisakazu Shindo; Nobuyuki Amino; Yasuhiro Ito; Minoru Kihara; Kaoru Kobayashi; Akihiro Miya; Mitsuyoshi Hirokawa; Akira Miyauchi
Journal:  Thyroid       Date:  2014-03-06       Impact factor: 6.568

6.  Transoral endoscopic thyroidectomy via a vestibular approach: why and how?

Authors:  Gianlorenzo Dionigi; Young Jun Chai; Ralph P Tufano; Angkoon Anuwong; Hoon Yub Kim
Journal:  Endocrine       Date:  2017-10-16       Impact factor: 3.633

7.  Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Authors:  Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Faisal S BinHumaid; Dania Alkhafaji; Roua A Al-Rijjal; Brian F Meyer; Yufei Shi
Journal:  Thyroid       Date:  2014-06-10       Impact factor: 6.568

8.  Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk.

Authors:  Enrico Papini; Rinaldo Guglielmi; Hossein Gharib; Gharib Hosseim; Irene Misischi; Filomena Graziano; Marco Chianelli; Anna Crescenzi; Antonio Bianchini; Dario Valle; Giancarlo Bizzarri
Journal:  Thyroid       Date:  2011-05-19       Impact factor: 6.568

9.  Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma: A Prospective Study.

Authors:  Mingbo Zhang; Yukun Luo; Yan Zhang; Jie Tang
Journal:  Thyroid       Date:  2016-08-18       Impact factor: 6.568

10.  BRAF mutation in papillary thyroid carcinoma.

Authors:  Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

View more
  5 in total

1.  Circ_0001658 regulates PI3K/AKT signaling via the miR-671-5p/ITGA2 axis and affects the progress of papillary thyroid carcinoma.

Authors:  Xiaoyu Liu; Congren Wang; Zijian Su; Shaoyang Cai; Qunxiong Pan; Xiangjin Chen
Journal:  Ann Transl Med       Date:  2022-09

2.  Transcription Factor E2F1 Exacerbates Papillary Thyroid Carcinoma Cell Growth and Invasion via Upregulation of LINC00152.

Authors:  Junjie Yang; Yong Ying; Xiangtai Zeng; Jiafeng Liu; Yang Xie; Zefu Deng; Zhiqiang Hu; Zanbin Li
Journal:  Anal Cell Pathol (Amst)       Date:  2022-05-10       Impact factor: 4.133

Review 3.  Efficacy and safety of radiofrequency ablation in the treatment of low-risk papillary thyroid carcinoma: a review.

Authors:  Spyridon Ntelis; Dimitrios Linos
Journal:  Hormones (Athens)       Date:  2021-04-06       Impact factor: 2.885

4.  Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4.

Authors:  Yan Liu; Hejia Zhang; Hui Wang; Jiarui Du; Peng Dong; Meihan Liu; Yuanqiang Lin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Papillary Thyroid Microcarcinoma: A Nomogram Based on Clinical and Ultrasound Features to Improve the Prediction of Lymph Node Metastases in the Central Compartment.

Authors:  Jing Ye; Jia-Wei Feng; Wan-Xiao Wu; Jun Hu; Li-Zhao Hong; An-Cheng Qin; Wei-Hai Shi; Yong Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.